Robin K Kelley

Summary

Publications

  1. pmc Biomarker use in colorectal cancer therapy
    Robin K Kelley
    University of California, San Francisco, CA, USA
    J Natl Compr Canc Netw 9:1293-302. 2011
  2. ncbi Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Am J Clin Oncol 35:411-7. 2012
  3. pmc Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
    Robin K Kelley
    University of California, San Francisco, The Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 10:73-80. 2011
  4. ncbi A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma
    Pelin Cinar
    Division of Hematology Oncology, Department of Medicine, University of California, San Francisco, CA, U S A
    Anticancer Res 34:7357-60. 2014
  5. doi Novel therapeutics in hepatocellular carcinoma
    Robin K Kelley
    From the University of California, San Francisco, San Francisco, CA
    Am Soc Clin Oncol Educ Book 2013:137-42. 2013
  6. pmc Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer
    Robin K Kelley
    Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
    J Natl Compr Canc Netw 9:13-25. 2011
  7. ncbi Predictive biomarkers in advance of a companion drug: ahead of their time?
    Robin K Kelley
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
    J Natl Compr Canc Netw 10:303-9. 2012

Collaborators

  • Alan P Venook
  • Emily K Bergsland
  • Pelin Cinar
  • Andrew H Ko
  • Sarah M Calkins
  • Elizabeth Dito
  • Anna Ong
  • Anne M Espinoza
  • Margaret A Tempero
  • Kimberly A Jones
  • Fergus V Coakley
  • Cherry S Hanover

Detail Information

Publications7

  1. pmc Biomarker use in colorectal cancer therapy
    Robin K Kelley
    University of California, San Francisco, CA, USA
    J Natl Compr Canc Netw 9:1293-302. 2011
    ..A selection of biomarkers undergoing validation for future clinical application is presented, and the dynamic and challenging interface between biomarkers in research and clinical practice is discussed...
  2. ncbi Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Am J Clin Oncol 35:411-7. 2012
    ....
  3. pmc Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
    Robin K Kelley
    University of California, San Francisco, The Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 10:73-80. 2011
    ..Current evidence for both of these assays is described below, concluding with a discussion of potential future directions for gene expression profiling in colon cancer risk stratification and treatment decision making...
  4. ncbi A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma
    Pelin Cinar
    Division of Hematology Oncology, Department of Medicine, University of California, San Francisco, CA, U S A
    Anticancer Res 34:7357-60. 2014
    ..Overexpression of the human epidermal growth factor 2 (HER2) is associated with an aggressive metastatic phenotype in patients with breast cancer but its prognostic impact is not well-characterized in gastroesophageal adenocarcinoma...
  5. doi Novel therapeutics in hepatocellular carcinoma
    Robin K Kelley
    From the University of California, San Francisco, San Francisco, CA
    Am Soc Clin Oncol Educ Book 2013:137-42. 2013
    ..Collectively, these and other new strategies are needed to make progress in identifying active novel therapeutics for patients with HCC...
  6. pmc Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer
    Robin K Kelley
    Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
    J Natl Compr Canc Netw 9:13-25. 2011
    ..Potential implications of this conclusion and future directions for research are discussed...
  7. ncbi Predictive biomarkers in advance of a companion drug: ahead of their time?
    Robin K Kelley
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
    J Natl Compr Canc Netw 10:303-9. 2012
    ..A great need exists for comprehensive and dynamic practice guidelines for all types of biomarker testing according to tumor type...